Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Capital Expenditures (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Capital Expenditures for 11 consecutive years, with -$93000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures fell 120.44% to -$93000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $18000.0 through Dec 2025, down 97.87% year-over-year, with the annual reading at $18000.0 for FY2025, 97.87% down from the prior year.
  • Capital Expenditures for Q4 2025 was -$93000.0 at Cartesian Therapeutics, up from -$577000.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $2.3 million in Q2 2024, with the low at -$2.5 million in Q3 2024.
  • Average Capital Expenditures over 5 years is $163950.0, with a median of $147000.0 recorded in 2021.
  • Peak annual rise in Capital Expenditures hit 3350.0% in 2024, while the deepest fall reached 2745.74% in 2024.
  • Over 5 years, Capital Expenditures stood at $278000.0 in 2021, then decreased by 24.1% to $211000.0 in 2022, then tumbled by 106.64% to -$14000.0 in 2023, then surged by 3350.0% to $455000.0 in 2024, then crashed by 120.44% to -$93000.0 in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at -$93000.0, -$577000.0, and -$387000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.